|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2006
Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study
1 Skin and Allergy Hospital, Helsinki University Central Hospital, 2 AstraZeneca, Helsinki, 4 Pikonlinna Hospital, Tampere University Hospital, Tampere, 5 Paimio Hospital, Turku University Central Hospital, Turku, Finland., 3 Center for Allergy, University Hospital, Linköping, 6 AstraZeneca, Södertälje, and 7 SEMECO AB, Lund, Sweden.
CORRESPONDENCE: T. Haahtela, Skin and Allergy Hospital, Helsinki University Central Hospital, FIN-00290 Helsinki, Finland. Fax: 358 947186500. E-mail: tari.haahtela{at}hus.fi
Keywords: Asthma guidelines, budesonide, exhaled nitric oxide, formoterol, mild intermittent asthma, Turbuhaler®
Received: November 2, 2005
Accepted May 26, 2006
Patients with mild intermittent asthma sometimes show signs of inflammation, and guidelines suggesting bronchodilator therapy alone as needed may be questioned.
The current study compared as-needed use of a rapid-acting ß2-agonist with as-needed use of a ß2-agonist and corticosteroid combination as the only medication in asthma patients with intermittent symptoms. A total of 92 nonsmoking asthma patients (of 187 screened) using only an inhaled ß2-agonist as needed (28 males, 64 females; mean age 37 yrs; mean forced expiratory volume in one second (FEV1) 101% predicted, mean reversibility 6.5% pred and fractional exhaled nitric oxide (FeNO)
The primary variable of efficacy was change in FeNO. Baseline FeNO was 60 ppb and 59 ppb in the budesonide/formoterol and formoterol groups, respectively. Mean reductions in FeNO in the budesonide/formoterol and formoterol groups were 18.2 ppb and 2.8 ppb, respectively (95% confidence interval (CI) 7.5–23.5 ppb). The reduction in the budesonide/formoterol group occurred during the first 4 weeks of treatment and remained at this low level. Mean FEV1 increased by 1.8% pred normal value in the budesonide/formoterol group and decreased by 0.9% pred normal value in the formoterol group (95% CI -4.7– -0.7). In the budesonide/formoterol group, use of
In conclusion, as-needed use of an inhaled corticosteroid together with a rapid-acting bronchodilator may be more beneficial than a ß2-agonist alone in patients with intermittent asthma and signs of airway inflammation. The long-term benefits are unknown.
20 parts per billion (ppb)) were randomised to treatment with formoterol (Oxis® Turbuhaler®) 4.5 µg as needed (n = 47) or budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5 µg as needed (n = 45) in a double-blind, parallel-group 24-week study. 4 inhalations·day-1 of study medication was seen on 21 treatment days compared with 74 in the formoterol group.
This article has been cited by other articles:
|
|
 |
|
  B. Dahlen, A-S. Lantz, E. Ihre, M. Skedinger, E. Henriksson, L. Jorgensen, T. Ekstrom, S-E. Dahlen, and K. Larsson Effect of formoterol with or without budesonide in repeated low-dose allergen challenge Eur. Respir. J., April 1, 2009; 33(4): 747 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rytila, L. Ghaly, S. Varghese, W. Chung, O. Selroos, T. Haahtela, and on behalf of the Airway Inflammation Study group Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Eur. Respir. J., October 1, 2008; 32(4): 989 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Lim and C. Mottram The Use of Fraction of Exhaled Nitric Oxide in Pulmonary Practice Chest, May 1, 2008; 133(5): 1232 - 1242. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |